19 research outputs found
On semi-planar Steiner quasigroups
No full textAbstractA Steiner triple system (briefly ST) is in 1–1 correspondence with a Steiner quasigroup or squag (briefly SQ) [B. Ganter, H. Werner, Co-ordinatizing Steiner systems, Ann. Discrete Math. 7 (1980) 3–24; C.C. Lindner, A. Rosa, Steiner quadruple systems: A survey, Discrete Math. 21 (1979) 147–181]. It is well known that for each n≡1 or 3 (mod 6) there is a planar squag of cardinality n [J. Doyen, Sur la structure de certains systems triples de Steiner, Math. Z. 111 (1969) 289–300]. Quackenbush expected that there should also be semi-planar squags [R.W. Quackenbush, Varieties of Steiner loops and Steiner quasigroups, Canad. J. Math. 28 (1976) 1187–1198]. A simple squag is semi-planar if every triangle either generates the whole squag or the 9-element squag. The first author has constructed a semi-planar squag of cardinality 3n for all n>3 and n≡1 or 3 (mod 6) [M.H. Armanious, Semi-planar Steiner quasigroups of cardinality 3n, Australas. J. Combin. 27 (2003) 13–27]. In fact, this construction supplies us with semi-planar squags having only nontrivial subsquags of cardinality 9. Our aim in this article is to give a recursive construction as n→3n for semi-planar squags. This construction permits us to construct semi-planar squags having nontrivial subsquags of cardinality >9. Consequently, we may say that there are semi-planar SQ(3mn)s (or semi-planar ST(3mn)s) for each positive integer m and each n≡1 or 3 (mod 6) with n>3 having only medial subsquags at most of cardinality 3ν (sub-ST(3)ν) for each ν∈{1,2,…,m+1}
Corrigendum to “NEAT1: Culprit lncRNA linking PIG C, MSLN, and CD80 in triple-negative breast cancer” [Life Sci., volume 299 (2022) 120523]
No full textThe authors regret that the name of one of the authors was not included in the original article due to an oversight. Monica Armanious, the omitted author, significantly contributed to this research work and her work was essential to the success of our project. Monica conducted the screening experiments in human tissues under the supervision of Dr. El Tayebi. Monica left the research career due to maternity circumstances during the publication process. Unfortunately, we figured out that her name was not mentioned in the final pdf submitted for publication by unintended error. This was recently noticed when Monica decided to continue pursuing research and publish her work to apply for PhD. The author names and the affiliations listed in this corrigendum are correct and complete. The authors would like to apologise for any inconvenience caused.</p
Semi-planar Steiner loops of cardinality 2n
No full textAbstractIt is well known that there is a planar sloop of cardinality n for each n≡2 or 4(mod6) (Math. Z. 111 (1969) 289–300). A semi-planar sloop is a simple sloop in which each triangle either generates the whole sloop or the 8-element sloop. In fact, Quackenbush (Canad. J. Math. 28 (1976) 1187–1198) has stated that there should be such semi-planar sloops. In this paper, we construct a semi-planar sloop of cardinality 2n for each n≡2 or 4(mod6). Consequently, we may say that there is a semi-planar sloop that is not planar of cardinality m for each m>16 and m≡4 or 8(mod12). Moreover, Quackenbush (Canad. J. Math. 28 (1976) 1187–1198) has proved that each finite simple planar sloop generates a variety, which covers the smallest non-trivial subvariety (the variety of all Boolean sloops) of the lattice of the subvarieties of all sloops. Similarly, it is easy to show that each finite semi-planar sloop generates another variety, which also covers the variety of all Boolean sloops. Furthermore, for any finite simple sloop L of cardinality n, the author (Beiträge Algebra Geom. 43 (2) (2002) 325–331) has constructed a subdirectly irreducible sloop S=2⊗pL of cardinality 2n and containing L as the only proper normal subsloop. Accordingly, if L is a semi-planar sloop, then the variety V(S) generated by S=2⊗pL properly contains the subvariety V(L)
Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge.
No full textINTRODUCTION: Pembrolizumab is an immune checkpoint inhibitor targeting the programmed death receptor with clinical effect on multiple malignancies including sarcoma. Associated cardio-toxicities include myocarditis, cardiomyopathy, heart failure, and arrhythmias. Although in most cases of immune checkpoint inhibitor cardiotoxicity the offending agent is discontinued, we report a case of successful and safe re-challenge with a checkpoint inhibitor in a patient with mild myocarditis.
CASE REPORT: We describe a 37-year-old female with alveolar soft part sarcoma, metastatic to the lungs on cycle 13 of pembrolizumab who presented with dyspnea, cough, and vague chest discomfort. Telemetry showed bigeminal bradycardia that transitioned to self-terminating torsades de pointes. Cardiac MRI showed subtle patchy T2 signal increase within the left ventricular septum without late gadolinium uptake, suggesting mild focal myocarditis.Management and outcome: The patient was started on a steroid taper without additional arrhythmias. We have re-challenged the patient who safely tolerated re-challenge with pembrolizumab despite an episode of torsades de pointes and documented myocarditis. She continues to receive pembrolizumab at seven months after the initial event without further cardiovascular events.
DISCUSSION: To the best of our knowledge, this is the first reported case of successful re-challenge of pembrolizumab after an episode of myocarditis. In patients with mild myocarditis and no evidence of left ventricular dysfunction, re-challenge may be a viable option. However, close monitoring for the development of heart failure, cardiomyopathy, or serious arrhythmias is necessary to ensure patient safety
Health care utilization and mortality associated with heart failure‐related admissions among cancer patients
No full textAims: Heart failure (HF) outcomes continue to improve with widespread use of new therapies. Concurrently, cancer survival has dramatically improved. Yet whether cancer patients share similar strategies and outcomes of inpatient HF treatment to those without HF is unknown. We sought to assess the contemporary impacts of cancer on inpatient HF outcomes over time.
Methods and results: The retrospective National Inpatient Sample (2003–15) and National Readmissions Database (2013–14) registries were queried for adults admitted for HF and stratified for cancer status, excluding cases of metastatic disease. Temporal trends in HF admissions, hospital charge rates, length of hospitalization, HF-related procedure utilization, in-hospital mortality, and hospital readmissions were analysed. Over 13 years of follow-up, there were 12 769 077 HF admissions (mean age 73 years, 50.8% female, 30.8% non-White), among which 1 413 287 (11%) had a co-morbid cancer diagnosis. Cancer patients were older, were predominantly male, and tended to be smokers. Over time, HF admission rates among cancer patients increased, despite a concurrent decrease among patients without cancer (P \u3c 0.0001). After propensity matching, in-hospital mortality was significantly higher among cancer HF patients (5.1% vs. 2.9%, P \u3c 0.0001). Additionally, HF-related procedure utilization was disproportionately lower among cancer patients (0.30 vs. 0.35 procedures/HF hospitalization, P \u3c 0.001); the presence of cancer was associated with increased costs, length of hospitalizations, and all-cause readmissions, but fewer HF readmissions (P \u3c 0.0001, each).
Conclusions: While the incidence of HF hospitalizations has increased among cancer patients, they do not appear to share the same rates of advanced HF care, readmissions trends, or reductions in in-hospital mortality. Future studies targeting modifiable factors related to these differences are needed
THE EFFECT OF A COMPREHENSIVE CARDIOVASCULAR RISK REDUCTION PROGRAM ON HEALTH-RELATED QUALITY OF LIFE AND FITNESS AMONG WOMEN WITH BREAST CANCER RECEIVING POTENTIALLY CARDIOTOXIC CHEMOTHERAPY
No full textInfluenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
No full textInfluenza vaccination (FV) is recommended for patients with cancer. Recent data suggested that the administration of the FV was associated with an increase in immune-related adverse events (irAEs) among patients on immune checkpoint inhibitors (ICIs). Myocarditis is an uncommon but serious complication of ICIs and may also result from infection with influenza. There are no data testing the relationship between FV and the development of myocarditis on ICIs
